Patents by Inventor Joyson Karakunnel

Joyson Karakunnel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS WITH AN ANTI HUMAN CD39 ANTIBODY, AN ANTI HUMAN PD-1 ANTIBODY, AND CHEMOTHERAPY IN GASTRIC CANCER
    Publication number: 20240150487
    Abstract: Provided herein are dosing and combination therapies with a CD39 antibody, a PD-1 antibody, and FOLFOX or CAPDX in gastric cancer.
    Type: Application
    Filed: March 6, 2023
    Publication date: May 9, 2024
    Inventors: Joyson Karakunnel, Achim Moesta, Courtney Beers, Alana Lerner, Benjamin Engelhardt, Akshanth R. Polepally, Daniel E.H. Afar, Peter S. Moon
  • Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
    Publication number: 20230115328
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Application
    Filed: August 9, 2022
    Publication date: April 13, 2023
    Inventors: RAJESH NARWAL, PAUL ROBBINS, JOYSON KARAKUNNEL, MOHAMMED DAR
  • Dosing with an azolopyrimidine compound
    Patent number: 11478479
    Abstract: Provided herein are methods of treating a disease, disorder, or condition, mediated at least in part by the adenosine A2A N receptor (A2AR) and/or the adenosine A2B receptor (A2BR) using Compound (I). In some embodiments, the disease or disorder is a cancer related disorder. Also provided herein are pharmaceutical compositions and single unit dosages of Compound (I).
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: October 25, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventor: Joyson Karakunnel
  • Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
    Patent number: 11446377
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: September 20, 2022
    Assignee: MEDIMMUNE, LLC
    Inventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
  • DOSING WITH AN AZOLOPYRIMIDINE COMPOUND
    Publication number: 20200405718
    Abstract: Provided herein are methods of treating a disease, disorder, or condition, mediated at least in part by the adenosine A2A N receptor (A2AR) and/or the adenosine A2B receptor (A2BR) using Compound (I). In some embodiments, the disease or disorder is a cancer related disorder. Also provided herein are pharmaceutical compositions and single unit dosages of Compound (I).
    Type: Application
    Filed: February 14, 2019
    Publication date: December 31, 2020
    Inventor: Joyson KARAKUNNEL, M.D.
  • ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER
    Publication number: 20190240324
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Application
    Filed: January 24, 2019
    Publication date: August 8, 2019
    Inventors: RAJESH NARWAL, PAUL ROBBINS, JOYSON KARAKUNNEL, MOHAMMED DAR
  • Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
    Patent number: 10232040
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 19, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
  • ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER
    Publication number: 20150328311
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Application
    Filed: May 12, 2015
    Publication date: November 19, 2015
    Inventors: Rajesh NARWAL, Paul Robbins, Joyson Karakunnel, Mohammed Dar